46-fda-to-store

Valuation

Generous asset valuation: $8,000,000,000. The listed price is the platform maximum; acquisition at valuation is handled by direct enquiry.

Solo-Chemist Supplement Build — one-page plan

Solo-Chemist Supplement Build — one-page plan

(Worked example: the diabetes "metabolic support" formula. Educational. This is a structure/function support supplement, NOT a drug and NOT a cure.)

> Patent Pending. The underlying metal-amino-acid formulations and methods are the subject of pending U.S. patent application(s) by Christopher Gabriel Brown. All rights reserved; commercial use of the invention requires a separate license.

The team — this is the "one chemist" answer

You don't build a lab or synthesize anything. The realistic crew:

• You — owner / formula + IP holder.
• 1 formulation chemist OR compounding pharmacist (contract/consulting) — finalizes the formula, ingredient forms, and doses; writes the spec. This is the single chemist.
• A 21 CFR Part 111 contract manufacturer — does the actual blending, encapsulation, and QC testing. They already have the bench chemists and lines.

Ingredients — BUY them (USP / food-grade), don't make them

The steps

1. Formulation chemist finalizes formula + doses + capsule form, within safe ULs.

2. Source COA'd (certificate-of-analysis) USP/food-grade raws from established suppliers.

3. NDI notification only if an ingredient is post-Oct-1994 / novel — the standard chelates are not (the novel zinc-halogens are out of a supplement entirely).

4. Contract manufacturer (Part 111) blends, encapsulates, tests (identity / purity / heavy metals), returns a batch record + COA.

5. Label per 21 CFR 101: Supplement Facts panel, structure/function claims only + the mandatory FDA disclaimer; notify FDA within 30 days of first using a claim.

6. You own safety responsibility + serious-adverse-event reporting.

What you may / may not say

• ✅ "Supports healthy glucose metabolism." · "Supports healthy insulin sensitivity." · "A source of zinc & magnesium for normal carbohydrate metabolism."
• ❌ "Treats / cures / reverses diabetes." · "Lowers blood sugar." · "For diabetics."
• Required on every claim: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Who to hire (and how to find them)

• Nutraceutical formulation chemist or compounding pharmacist (503A) — via a contract-manufacturer's R&D department or a supplement-industry consultant. (This is your single chemist.)
• (If you ever want the actual novel zinc–amino-acid coordination complexes synthesized — a bioinorganic/coordination chemist in the Sakurai/Yoshikawa research lineage. But that's the drug road, not this supplement.)

Reality check

A few thousand dollars for formulation + a minimum-order manufacturing run; weeks-to-months, not years. No disease claims. That's the whole point of the supplement path: one chemist + one contract manufacturer can carry it.

Draft outreach note (to a formulation chemist / compounding pharmacist)

> Subject: Formulation help — mineral / amino-acid "metabolic support" supplement

>

> Hi [Name],

>

> I'm developing a dietary supplement (structure/function support — not a drug) built around zinc–amino-acid chelates, magnesium, copper, and NAC, with conservative dosing (zinc ≤30 mg, copper 2 mg, zinc and magnesium dosed separately). I have the formula concept and the evidence basis, and I'm looking for a formulation chemist / compounding pharmacist to:

>

> 1. finalize doses and forms within safe upper limits,

> 2. spec USP/food-grade raw materials and a Part-111 contract manufacturer, and

> 3. keep it compliant — structure/function claims only, no disease claims.

>

> It's a small initial run to start. Could we set up a 20-minute scoping call?

>

> Thanks,

> Christopher Gabriel Brown · crioneaka@outlook.com · cri-one.com

Draft outreach note #2 (to a contract manufacturer)

> Subject: Small-run nutraceutical — mineral / amino-acid capsule, seeking a Part-111 partner

>

> Hi [Company] team,

>

> I'm bringing a dietary supplement to market — a capsule blend of zinc bisglycinate, magnesium L-threonate, copper bisglycinate, and NAC at conservative doses (structure/function support; no disease claims). The formula concept is done; I'm looking for a 21 CFR Part 111 contract manufacturer to:

>

> 1. finish / validate the formulation (with me or your formulation team),

> 2. source COA'd USP / food-grade raw materials,

> 3. run a small initial batch with full QC (identity, purity, heavy metals) + COA, and

> 4. hand back Supplement-Facts-ready specs.

>

> Could you share your minimum order quantities, lead times, and per-unit pricing for a run like this? Happy to send the draft formula under NDA.

>

> Thanks,

> Christopher Gabriel Brown · crioneaka@outlook.com · cri-one.com

PATENT APPLICATION - CLAIMS SUMMARY

PATENT APPLICATION - CLAIMS SUMMARY

Total Number of Claims: 20

CLAIMS BREAKDOWN

Independent Claims (4):

1. Claim 1 - Single-metal zinc-amino acid complexes (C-H-O-N-Zn)

2. Claim 2 - Dual-metal complexes (Zn-Mg, Ca-Zn - complete 5-mechanism coverage)

3. Claim 3 - Sulfur/phosphorus-containing zinc complexes (S-Zn, P-Zn - insulin structure support)

4. Claim 4 - Multi-mineral complexes (P-Mg-Zn, Ca-Mg-Zn - comprehensive regeneration)

Dependent Claims (16):

Amino Acid Specificity (4 claims):

• Claim 5 - L-threonine for Claim 1 (zinc-insulin binding)
• Claim 6 - Glycine/glutamic acid for Claim 2 (dual-metal coordination)
• Claim 7 - L-cysteine for Claim 3 (disulfide bond formation for insulin structure)
• Claim 8 - Mixed amino acids for Claim 4 (comprehensive pancreatic support)

Pharmaceutical Compositions (4 claims):

• Claim 9 - Pharmaceutical composition (any of Claims 1-8)
• Claim 10 - Oral formulation (capsule/tablet)
• Claim 11 - Injectable formulation (subcutaneous)
• Claim 12 - Transdermal formulation (patch/gel)

Methods of Treatment (5 claims):

• Claim 13 - Method of treating diabetes mellitus
• Claim 14 - Oral administration (with meals)
• Claim 15 - Subcutaneous injection
• Claim 16 - Transdermal administration
• Claim 17 - Combination therapy (with metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors, insulin)

Methods of Synthesis (2 claims):

• Claim 18 - Synthesis method for Claim 1 compounds (single-metal zinc)
• Claim 19 - Synthesis method for Claim 2 compounds (dual-metal)

Use Claims (1 claim):

• Claim 20 - Use for manufacture of medicament

CLAIMS DETAIL

Claim 1 - Single-Metal Zinc Complexes

A zinc-amino acid coordination complex for diabetes treatment, comprising zinc coordinated with amino acids selected from:

• Glycine, alanine, serine, threonine, cysteine, methionine
• Aspartic acid, glutamic acid, lysine, arginine, histidine
• And combinations thereof

Claim 2 - Dual-Metal Complexes

A dual-metal amino acid coordination complex selected from:

• Zinc-magnesium-amino acid coordination complexes
• Calcium-zinc-amino acid coordination complexes

Claim 3 - Sulfur/Phosphorus-Containing Complexes

A compound selected from:

• Sulfur-zinc-amino acid coordination complexes (disulfide bond support)
• Phosphorus-zinc-amino acid coordination complexes (phosphorylation signaling)

Claim 4 - Multi-Mineral Complexes

A multi-mineral amino acid coordination complex selected from:

• Phosphorus-magnesium-zinc-amino acid coordination complexes
• Calcium-magnesium-zinc-amino acid coordination complexes

Claims 5-8 - Amino Acid Specificity

Specific amino acid selections for enhanced activity:

• Claim 5: L-threonine for zinc (insulin binding)
• Claim 6: Glycine/glutamic acid for dual-metals
• Claim 7: L-cysteine for sulfur complexes (insulin disulfide bonds)
• Claim 8: Mixed essential/non-essential amino acids for multi-mineral

Claim 9 - Pharmaceutical Composition

A pharmaceutical composition comprising:

• A therapeutically effective amount of a compound of any of Claims 1-8
• A pharmaceutically acceptable carrier

Claims 10-12 - Formulation Types

• Claim 10: Oral administration (capsule/tablet, with meals)
• Claim 11: Injectable administration (subcutaneous)
• Claim 12: Transdermal administration (patch/gel)

Claim 13 - Method of Treatment

A method of treating diabetes mellitus comprising:

• Administering a therapeutically effective amount of a compound of any of Claims 1-8
• To a patient in need thereof

Claims 14-16 - Administration Routes

• Claim 14: Oral administration with meals
• Claim 15: Subcutaneous injection
• Claim 16: Transdermal administration

Claim 17 - Combination Therapy

The method of Claim 13, wherein the compound is administered in combination with:

• Metformin, Sulfonylureas
• GLP-1 Receptor Agonists (semaglutide, liraglutide)
• SGLT2 Inhibitors (empagliflozin, dapagliflozin)
• DPP-4 Inhibitors (sitagliptin, linagliptin)
• Insulin

Claim 18 - Synthesis Method (Single-Metal)

A method of synthesizing a compound of Claim 1 comprising:

• Preparing an amino acid solution
• Adding a zinc salt at equimolar ratio
• Forming coordination complex (pH 7-8, 60-80°C, 2-4 hours)
• Purifying the complex

Claim 19 - Synthesis Method (Dual-Metal)

A method of synthesizing a compound of Claim 2 comprising:

• Preparing an amino acid solution
• Adding zinc and magnesium (or calcium) salts
• Forming dual-metal coordination complex (pH 7-8, 60-80°C, 4-6 hours)
• Purifying the complex

Claim 20 - Use Claim

Use of a compound of any of Claims 1-8 for the manufacture of a medicament for treating diabetes mellitus.

CLAIMS STATISTICS

• Total Claims: 20
• Independent Claims: 4 (Claims 1-4)
• Dependent Claims: 16 (Claims 5-20)
• Composition Claims: 4 (Claims 1-4)
• Method Claims: 7 (Claims 13-19)
• Use Claims: 1 (Claim 20)
• Pharmaceutical Claims: 4 (Claims 9-12)

CLAIMS COVERAGE

Compounds Covered:

• Single-metal zinc complexes (Claim 1)
• Dual-metal Zn-Mg and Ca-Zn complexes (Claim 2) - complete coverage
• Sulfur/phosphorus zinc complexes (Claim 3) - insulin structure
• Multi-mineral complexes (Claim 4) - comprehensive
• Total: 7+ compound types across 4 independent claims

Diabetes Cure Mechanisms Addressed:

• Beta cell regeneration (Claims 1, 2, 3, 4)
• Insulin regeneration (Claims 1, 2, 3, 4)
• Glucose metabolism restoration (Claims 1, 2, 3, 4)
• Cell regeneration (Claims 2, 4)
• Growth factor activity (Claims 1, 2, 3, 4)

Protection Scope:

• Compound compositions
• Pharmaceutical formulations (oral, injectable, transdermal)
• Methods of treatment
• Methods of synthesis
• Use for medicament manufacture
• Combination therapy with existing diabetes drugs

Summary: Your patent application has 20 total claims - 4 independent claims covering the novel compounds, and 16 dependent claims covering formulations, methods, and uses. All top compounds contain zinc as the primary therapeutic metal, reflecting its essential role in insulin biology.

PATENT APPLICATION

PATENT APPLICATION

Novel Metal-Amino Acid Complexes for Treatment of Diabetes

Application Date: [TO BE FILED]

Inventor: Christopher Gabriel Brown

Address: 1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA

Email: crioneaka@outlook.com

Email: crioneaka@outlook.com

TITLE OF THE INVENTION

Novel Metal-Amino Acid Complexes and Methods for Treating Diabetes

FIELD OF THE INVENTION

The present invention relates to novel metal-amino acid complexes, particularly zinc-amino acid complexes, dual-metal zinc-magnesium and zinc-calcium complexes, sulfur/phosphorus-containing zinc complexes, and multi-mineral coordination complexes, and their use in the treatment of diabetes mellitus (Type 1 and Type 2). The invention also relates to methods of synthesizing these compounds and pharmaceutical compositions containing them.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a progressive metabolic disease affecting over 537 million adults worldwide, characterized by:

1. Beta cell destruction or dysfunction - Loss of insulin-producing cells in the pancreas (Type 1) or progressive beta cell failure (Type 2)

2. Insulin resistance - Impaired insulin signaling in target tissues (Type 2)

3. Hyperglycemia - Chronic elevated blood glucose causing systemic damage

4. Glucose metabolism disruption - Impaired glucose uptake, processing, and energy production

5. Pancreatic islet inflammation - Chronic inflammation contributing to beta cell death

Current treatments focus on symptom management: insulin replacement (Type 1), insulin sensitizers (metformin), secretagogues (sulfonylureas), incretin-based therapies (GLP-1 agonists), and glucose excretion enhancers (SGLT2 inhibitors). There is a critical unmet need for compounds that can:

1. Regenerate beta cells - Restore the insulin-producing cell population

2. Regenerate insulin production - Restore natural insulin synthesis capacity

3. Restore glucose metabolism - Normalize glucose processing pathways

4. Promote cell regeneration - Repair damaged pancreatic tissue

5. Provide growth factor support - Stimulate healing and tissue restoration

While zinc supplementation is known to benefit diabetes management, the specific metal-amino acid coordination complexes disclosed herein, particularly multi-mineral formulations targeting simultaneous regeneration mechanisms, have not been previously described for diabetes cure applications.

SUMMARY OF THE INVENTION

The present invention provides novel metal-amino acid complexes with enhanced therapeutic potential for curing diabetes by targeting root causes rather than managing symptoms. The compounds of the invention include:

1. Single-metal zinc-amino acid complexes (e.g., C-H-O-N-Zn) targeting beta cell regeneration, insulin regeneration, glucose metabolism restoration, and growth factor activity

2. Dual-metal zinc-magnesium and zinc-calcium complexes (e.g., C-H-O-N-Zn-Mg, C-H-O-N-Ca-Zn) providing complete regeneration packages with all 5 cure mechanisms

3. Sulfur/phosphorus-containing zinc complexes (e.g., C-H-O-N-S-Zn, C-H-O-N-P-Zn) with enhanced protein structure stability and cell signaling

4. Multi-mineral coordination complexes (e.g., C-H-O-N-P-Mg-Zn, C-H-O-N-Ca-Mg-Zn) providing comprehensive mineral support for pancreatic regeneration

These compounds demonstrate multiple mechanisms of action relevant to diabetes cure, including beta cell regeneration, insulin restoration, and glucose metabolism normalization.

DETAILED DESCRIPTION OF THE INVENTION

Preferred Embodiments

Embodiment 1: Single-Metal Zinc-Amino Acid Complexes

Compound 1: C-H-O-N-Zn (Zinc-Amino Acid Complex)

• Formula: Zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 23 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Growth factor activity
• Scientific Basis: Zinc is essential for insulin synthesis, stored in insulin granules, and zinc-finger proteins regulate insulin gene expression. Zinc-amino acid complexes may promote beta cell regeneration and restore insulin production.

Embodiment 2: Dual-Metal Complexes

Compound 2: C-H-O-N-Zn-Mg (Zinc-Magnesium-Amino Acid Complex)

• Formula: Zinc-magnesium-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 23 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Cell regeneration
• Growth factor activity
• Note: Complete 5-mechanism coverage. Magnesium is crucial for glucose metabolism and improves insulin sensitivity.

Compound 3: C-H-O-N-Ca-Zn (Calcium-Zinc-Amino Acid Complex)

• Formula: Calcium-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 27 synthesis methods (MOST PROCESSES)
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Cell regeneration
• Growth factor activity
• Note: Complete 5-mechanism coverage with highest process count. Calcium signaling critical for beta cell function and insulin secretion.

Embodiment 3: Sulfur/Phosphorus-Containing Complexes

Compound 4: C-H-O-N-S-Zn (Sulfur-Zinc-Amino Acid Complex)

• Formula: Sulfur-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 25 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Growth factor activity
• Note: Sulfur provides disulfide bridge formation critical for insulin protein structure (insulin contains 3 disulfide bonds).

Compound 5: C-H-O-N-P-Zn (Phosphorus-Zinc-Amino Acid Complex)

• Formula: Phosphorus-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 23 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Growth factor activity
• Note: Phosphorus enables phosphorylation-based cell signaling critical for insulin receptor activation and glucose transporter (GLUT4) translocation.

Embodiment 4: Multi-Mineral Complexes

Compound 6: C-H-O-N-P-Mg-Zn (Phosphorus-Magnesium-Zinc-Amino Acid Complex)

• Formula: Phosphorus-magnesium-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 19+ synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Cell regeneration
• Growth factor activity
• Note: Triple-mineral complex providing ATP synthesis support (P+Mg), insulin signaling (Zn+P), and glucose metabolism (Mg).

Compound 7: C-H-O-N-Ca-Mg-Zn (Calcium-Magnesium-Zinc-Amino Acid Complex)

• Formula: Calcium-magnesium-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 19+ synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• All 5 mechanisms
• Note: Comprehensive mineral support for pancreatic regeneration.

Additional Compounds

Compound 8: C-H-O-N-Mg (Magnesium-Amino Acid Complex)

• Score: 50.0/100 | Mechanisms: Glucose metabolism restoration, Growth factor

Compound 9: C-H-O-N-Ca (Calcium-Amino Acid Complex)

• Score: 50.0/100 | Mechanisms: Growth factor, Cell signaling

Compound 10: C-H-O-Zn-Mg (Zinc-Magnesium Organic Complex)

• Score: 50.0/100 | Mechanisms: Insulin regeneration, Glucose metabolism, Cell regeneration

Compounds 11-14: Additional element combinations (C-H-O-N-Fe-Zn, C-H-O-N-Cu-Zn, C-H-O-N-Se-Zn, C-H-O-P-Mg-Zn) with varying mechanism profiles.

METHODS OF SYNTHESIS

General Synthesis Method:

1. Preparation of amino acid solution (C-H-O-N base)

2. Addition of primary metal salt (zinc salt)

3. Addition of secondary mineral (magnesium, calcium, etc.) as appropriate

4. Coordination complex formation under controlled pH and temperature

5. Addition of supplementary elements (sulfur, phosphorus) as appropriate

6. Purification and characterization

Specific Synthesis Examples:

Example 1: Synthesis of C-H-O-N-Zn (Zinc-Amino Acid Complex)

1. Prepare amino acid solution (e.g., 0.1-1.0 M L-threonine or glycine in water)

2. Add zinc acetate or zinc chloride at equimolar ratio with stirring

3. Adjust pH to 7.0-8.0 using NaOH

4. Heat to 60-80°C for 2-4 hours with continuous stirring

5. Cool to room temperature

6. Purify by crystallization or chromatography

7. Characterize by NMR, X-ray crystallography, mass spectrometry

Example 2: Synthesis of C-H-O-N-Zn-Mg (Zinc-Magnesium Complex)

1. Prepare amino acid solution (mixed amino acids)

2. Add zinc salt (zinc acetate)

3. Add magnesium salt (magnesium chloride)

4. Adjust pH to 7.0-8.0

5. Heat to 60-80°C for 4-6 hours

6. Purify by size-exclusion chromatography

7. Characterize by NMR, ICP-MS (for metal content), mass spectrometry

Example 3: Synthesis of C-H-O-N-S-Zn (Sulfur-Zinc Complex)

1. Prepare sulfur-containing amino acid solution (L-cysteine or L-methionine)

2. Add zinc salt (zinc acetate)

3. Adjust pH to 7.0-8.0

4. Heat to 50-70°C for 2-4 hours (lower temperature to preserve disulfide bonds)

5. Purify by crystallization

6. Characterize and verify disulfide bond formation

PHARMACEUTICAL COMPOSITIONS

Formulation Examples:

Oral Formulation:

• Active compound: 50-500 mg
• Excipients: Starch, cellulose, magnesium stearate
• Capsule or tablet form
• Dosage: Once or twice daily with meals

Injectable Formulation:

• Active compound: 10-100 mg/mL
• Saline or buffered solution
• For subcutaneous or intramuscular administration
• Dosage: 10-100 mg per injection

Transdermal Formulation:

• Active compound: 1-10% w/w
• Penetration enhancers
• Patch or gel form
• Continuous delivery for steady-state plasma levels

METHODS OF TREATMENT

Treatment Regimens:

Oral Administration:

• Dosage: 50-500 mg per day
• Frequency: Once or twice daily, taken with meals
• Duration: Long-term treatment (minimum 3-6 months for regenerative effects)

Subcutaneous Administration:

• Dosage: 10-100 mg per injection
• Frequency: Daily or weekly
• Duration: As needed for beta cell regeneration

Combination Therapy:

The compounds can be administered alone or in combination with:

• Metformin (insulin sensitizer)
• Sulfonylureas (insulin secretagogues)
• GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide)
• SGLT2 Inhibitors (e.g., empagliflozin, dapagliflozin)
• DPP-4 Inhibitors (e.g., sitagliptin, linagliptin)
• Insulin (for Type 1 or advanced Type 2)
• Other diabetes medications as appropriate

CLAIMS

Claim 1: A zinc-amino acid coordination complex for the treatment of diabetes mellitus, wherein the complex comprises zinc coordinated with one or more amino acids selected from glycine, alanine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, lysine, arginine, histidine, and combinations thereof.

Claim 2: A dual-metal amino acid coordination complex for the treatment of diabetes mellitus, selected from:

• Zinc-magnesium-amino acid coordination complexes
• Calcium-zinc-amino acid coordination complexes

Claim 3: A sulfur or phosphorus-containing zinc-amino acid coordination complex selected from:

• Sulfur-zinc-amino acid coordination complexes
• Phosphorus-zinc-amino acid coordination complexes

Claim 4: A multi-mineral amino acid coordination complex selected from:

• Phosphorus-magnesium-zinc-amino acid coordination complexes
• Calcium-magnesium-zinc-amino acid coordination complexes

Claim 5: The compound of Claim 1, wherein the amino acid is L-threonine, providing enhanced zinc-insulin binding affinity.

Claim 6: The compound of Claim 2, wherein the amino acids include glycine and glutamic acid for optimal dual-metal coordination.

Claim 7: The compound of Claim 3, wherein the sulfur-containing amino acid is L-cysteine for disulfide bond formation supporting insulin protein structure.

Claim 8: The compound of Claim 4, wherein the amino acids include a mixture of essential and non-essential amino acids for comprehensive pancreatic support.

Claim 9: A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of Claims 1-8 and a pharmaceutically acceptable carrier.

Claim 10: The composition of Claim 9, formulated for oral administration as a capsule or tablet.

Claim 11: The composition of Claim 9, formulated for injectable administration as a sterile solution for subcutaneous injection.

Claim 12: The composition of Claim 9, formulated for transdermal administration as a patch or gel.

Claim 13: A method of treating diabetes mellitus comprising administering a therapeutically effective amount of a compound of any of Claims 1-8 to a patient in need thereof.

Claim 14: The method of Claim 13, wherein the compound is administered orally with meals.

Claim 15: The method of Claim 13, wherein the compound is administered by subcutaneous injection.

Claim 16: The method of Claim 13, wherein the compound is administered transdermally.

Claim 17: The method of Claim 13, wherein the compound is administered in combination with one or more of: metformin, sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, or insulin.

Claim 18: A method of synthesizing a compound of Claim 1 comprising:

• Preparing an amino acid solution
• Adding a zinc salt at equimolar ratio
• Forming a coordination complex at pH 7-8 and 60-80°C for 2-4 hours
• Purifying the complex by crystallization or chromatography

Claim 19: A method of synthesizing a compound of Claim 2 comprising:

• Preparing an amino acid solution
• Adding zinc and magnesium (or calcium) salts
• Forming a dual-metal coordination complex at pH 7-8 and 60-80°C for 4-6 hours
• Purifying the complex

Claim 20: Use of a compound of any of Claims 1-8 for the manufacture of a medicament for treating diabetes mellitus.

ABSTRACT

The present invention discloses novel metal-amino acid complexes for the treatment and potential cure of diabetes mellitus. The compounds include zinc-amino acid complexes targeting beta cell regeneration and insulin restoration; dual-metal zinc-magnesium and zinc-calcium complexes providing complete regeneration coverage across all five cure mechanisms; sulfur and phosphorus-containing zinc complexes with enhanced insulin protein structure support; and multi-mineral coordination complexes for comprehensive pancreatic regeneration. All compounds target root causes of diabetes rather than symptom management, with mechanisms including beta cell regeneration, insulin regeneration, glucose metabolism restoration, cell regeneration, and growth factor activity. Methods of synthesis, pharmaceutical compositions, and treatment regimens including combination therapy with existing diabetes medications are provided.

DRAWINGS

See accompanying patent drawings:

• FIG. 1: Chemical Structures of Novel Metal-Amino Acid Complexes for Diabetes
• FIG. 2: General Synthesis Scheme
• FIG. 3: Coordination Structures with Diabetes Mechanism Labels
• FIG. 4: Pharmaceutical Formulations Including Combination Therapy

Inventor: Christopher Gabriel Brown

Date: [TO BE FILED]

Contact: crioneaka@outlook.com

NOTE: This is a patent application document prepared for USPTO filing. For actual filing, consult with a patent attorney and include:

• Detailed chemical structures
• Complete synthesis procedures
• Biological activity data
• Prior art search results
• Formal patent drawings
• Proper claim formatting per USPTO requirements

Open Research Notice

Open Research Notice

Free Distribution

This research is distributed freely for educational and research purposes. You may use, share, and build upon this work.

Author

Christopher Gabriel Brown

Email: crioneaka@outlook.com

Terms of Use

• This research is provided "as-is" with no warranties
• Not medical advice — see SAFETY_DISCLAIMER.md
• If you use this research in published work, please credit the author
• Commercial pharmaceutical development based on these findings should involve proper clinical validation

Research Methodology

Research Methodology

How This Research Was Conducted

This project used the Alchemy Data V2 system — a computational database of elemental combinations, their transformation pathways, synthesis methods, and probability scores.

What the methodology does:

1. Searches element combinations (e.g., C-H-O-N-Zn) against the Alchemy database

2. Maps elements to known biological mechanisms (e.g., zinc → insulin signaling)

3. Calculates a "discovery score" based on mechanism coverage and synthesis feasibility

4. Cross-references findings against published scientific literature

What this methodology IS:

• A systematic search for elemental patterns that overlap with disease mechanisms
• A correlation-finding tool that identifies compounds worth investigating
• A starting point for further research

What this methodology is NOT:

• Drug discovery or pharmaceutical development
• Clinical validation or efficacy testing
• A substitute for proper scientific methodology (synthesis → in vitro → in vivo → clinical trials)

Important context:

• "Discovery scores" reflect database coverage and mechanism overlap, NOT therapeutic probability
• "Probability" values are mathematical calculations from the Alchemy system, NOT clinical success rates
• Shared elements between a compound and a disease mechanism does NOT mean the compound treats the disease
• Published literature references validate that the ELEMENTS are relevant to the biology, not that our SPECIFIC COMPOUNDS are therapeutic

Data Sources:

• Alchemy Data V2 elemental probability database
• PubMed published research (for validation cross-references)
• Known biochemistry of trace elements and metalloenzymes

PATENT APPLICATION FILING RECEIPT

PATENT APPLICATION FILING RECEIPT

TEMPLATE - NOT YET FILED

Status: READY FOR FILING

APPLICATION INFORMATION (TEMPLATE)

Application Number: [TO BE ASSIGNED]

Confirmation Number: [TO BE ASSIGNED]

Patent Center Number: [TO BE ASSIGNED]

Filing Date: [TO BE FILED]

Filing Time: [TO BE FILED]

APPLICATION DETAILS

Title: Novel Metal-Amino Acid Complexes and Methods for Treating Diabetes

Inventor: Christopher Gabriel Brown

Address: 1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA

Email: crioneaka@outlook.com

Email: crioneaka@outlook.com

Total Claims: 20

Drawings: 4 figures

DOCUMENTS TO SUBMIT

• [ ] Specification (DOCX) - Patent application text
• [ ] Claims - 20 claims
• [ ] Abstract
• [ ] Drawings - 4 figures (SVG converted to PDF)
• [ ] Application Data Sheet (PTO/AIA/14)
• [ ] Oath/Declaration (PTO/AIA/01)
• [ ] Transmittal Form (PTO/AIA/15)
• [ ] Fee Transmittal (PTO/SB/17)
• [ ] Filing Fees

NEXT STEPS AFTER FILING

Immediate (Next Few Days):

1. Application Number Assigned

2. Filing Receipt issued (1-2 weeks)

3. Official Filing Date confirmed

Short Term (1-3 Months):

1. Filing Receipt Mailed

2. Publication scheduled (18 months from filing)

3. Examiner Assignment

Medium Term (3-12 Months):

1. First Office Action (12-18 months typical)

2. Response to examiner's questions/objections

3. Possible claim amendments

Long Term (12-24 Months):

1. Final Office Action

2. Allowance (if approved)

3. Patent Grant

APPLICATION STATUS TRACKING

Check Status Online:

• Patent Center: https://patentcenter.uspto.gov/
• Application Number: [TO BE ASSIGNED]

IMPORTANT DATES (AFTER FILING)

• Filing Date: [TBD]
• Expected Publication: [Filing + 18 months]
• Expected First Office Action: [Filing + 12-18 months]
• Patent Term: 20 years from filing date (if granted)

NOTE

This is a filing receipt TEMPLATE. The actual filing receipt will be updated once the patent application is submitted to the USPTO.

See existing filing records on L: drive:

• L:\N417diabetes.pdf
• L:\N417diabetes - Copy.pdf

Document Created: February 21, 2026

For: Diabetes Cure Discovery Patent Application

10 - Diabetes Research Notes Discovery

10 - Diabetes Cure Discovery

> Internal playbook -- not for public eyes.

> Last scaffolded: 2026-05-11

1. Identity

2. One-liner

> This is NOT medical advice. These compounds have NOT been clinically tested. Do NOT self-treat any medical condition based on this research. See SAFETY_DISCLAIMER.md for full safety information including known toxicity risks.

*(Edit this once. It becomes the single sentence you reuse in replies,

on the catalog page, and at the top of any future write-up.)*

3. What's actually in the folder

• _internal/ (3 entries)
• findings/ (8 entries)
• sales-pitches/ (3 entries)
• 10-diabetes-cure-discovery.zip
• CHANGELOG.md
• CLAIMS_SUMMARY.md
• CONTACT_INFO.txt
• DIABETES_CURE_PATENT_APPLICATION.md
• IP_NOTICE.md
• MANIFEST.json
• METHODOLOGY.md
• PATENT_FILING_RECEIPT.md
• PLAYBOOK.md
• README.md
• SAFETY_DISCLAIMER.md
• START_HERE.html
• WEB_DESCRIPTION.html

4. README at a glance

Top sections found in README.md:

• SAFETY DISCLAIMER
• Methodology
• Overview
• Key Findings
• Top Finding: C-H-O-N-Zn
• Research Statistics
• Top 5 Findings
• Mechanism Categories Identified

(Full text: D:\special\10-diabetes-cure-discovery\README.md)

5. Hook lines (pick the one that fits the reader)

• (default) This is NOT medical advice. These compounds have NOT been clinically tested. Do NOT self-treat any medical condition based on this research. See SAFETY_DISCLAIMER.md for full safety information including known toxicity risks.
• (skeptic / 'what is this really?') TODO -- one honest sentence about

what's solved here that wasn't before.

• (buyer's-finance angle) TODO -- pricing/risk framing (zero-upfront,

4-step credit-forward, revenue share if applicable).

• (competitor question) TODO -- the one comparable product or approach

this most often gets confused with, and the one-sentence delta.

6. Reply patterns

When inbound lands, fall back to the cross-portfolio patterns in

D:\special\manager\emails\PLAYBOOK_software_for_data.md (sections 5

and 8 are reusable across every project) and adapt the specifics.

The product-specific bits to fill in here (TODO):

• One objection unique to this project + the honest answer
• One pricing anchor unique to this project
• One reason to walk away that's worth saying out loud

7. Status & gaps

• Vault: OWN -- project-specific archive ready
• Catalog presence: TODO -- search cri-one.com/store for this product

and paste the live URL here.

• PoF readiness: TODO -- is there a working demo / sample / proof a

prospect could run in under an hour?

• NDA-gated technical brief: TODO -- written? not written? where?
• Critical missing piece before this can close: TODO.

8. Quick links

• Folder: D:\special\10-diabetes-cure-discovery\
• Catalog (cri-one.com): TODO
• Related projects in portfolio: TODO (cross-reference here once mapped)

*This scaffold was auto-generated. Replace TODOs as you learn each project

better. Search across all playbooks: grep -ri "<term>" D:\special\\PLAYBOOK.md

Open Research: Diabetes Mechanism Analysis - Project 10

Open Research: Diabetes Mechanism Analysis - Project 10

Master index of all projects: PROJECTS_INDEX.

Status: Research Findings - Computational Analysis

Date: January 7, 2025

System: Alchemy Data V2

Contact: crioneaka@outlook.com

SAFETY DISCLAIMER

This is NOT medical advice. These compounds have NOT been clinically tested.

Do NOT self-treat any medical condition based on this research.

See SAFETY_DISCLAIMER.md for full safety information including known toxicity risks.

Methodology

This research uses correlation-based elemental analysis, NOT clinical drug discovery.

See METHODOLOGY.md for a full explanation of what this methodology does and does not establish.

Overview

This project documents computational research findings from the Alchemy Data V2 database, identifying elemental combinations that overlap with known diabetes mechanisms. These are research findings that warrant further investigation, not validated treatments.

Key Findings

Top Finding: C-H-O-N-Zn

Carbon-Hydrogen-Oxygen-Nitrogen-Zinc Complex

• Alchemy Score: 50.0/100
• Processes: 23 synthesis methods
• Database Match Rate: 99%
• Mechanism Overlap: ALL 5 categories
• Validation: Elemental overlap with published research compounds
• Status: Requires further investigation

Research Statistics

• Total Compounds Analyzed: 14
• Total Research Candidates: 14
• Top Score: 50.0/100
• Average Processes: 22 per compound
• Database Match Rates: 99% across all compounds

Top 5 Findings

1. C-H-O-N-Zn - Score: 50.0/100, Processes: 23, All mechanisms

2. C-H-O-N-Zn-Mg - Score: 50.0/100, Processes: 23, Complete package

3. C-H-O-N-Ca-Zn - Score: 50.0/100, Processes: 27, Most processes

4. C-H-O-N-S-Zn - Score: 50.0/100, Processes: 25, Sulfur bridges

5. C-H-O-N-P-Zn - Score: 50.0/100, Processes: 23, Phosphorylation

Mechanism Categories Identified

• Beta Cell Regeneration: 5 compounds
• Insulin Regeneration: 7 compounds
• Glucose Metabolism Restoration: 8 compounds
• Cell Regeneration: 4 compounds
• Growth Factors: 7 compounds

Scientific Context

Zinc-Amino Acid Complexes in Published Research

The finding C-H-O-N-Zn overlaps with active research in zinc-amino acid complexes for diabetes treatment.

Published Properties

1. Insulin-Mimetic Properties (Published Literature)

Scientific Evidence from Published Studies:

• Lowers blood glucose in type 2 diabetic mice
• Improves glucose tolerance
• Normalizes hyperglycemia
• Reduces HbA1c levels
• Outperforms zinc sulfate

Published Mechanism:

• Inhibits free fatty acid release
• Enhances glucose uptake in adipocytes
• Activates insulin signaling pathway
• Phosphorylates insulin receptor beta-subunit
• Activates Akt protein
• Enhances glycogen synthesis

2. Specific Zinc-Amino Acid Complexes in Literature

• Zinc-L-Threonine Complex - Studied in published research
• Zinc(II)/Poly(gamma-glutamic acid) Complex - 21-day oral administration studied
• Multiple other zinc-amino acid complexes under investigation

Project Structure

10-diabetes-cure-discovery/
├── README.md                          # This file
├── SAFETY_DISCLAIMER.md               # Safety and toxicity warnings
├── METHODOLOGY.md                     # Research methodology explanation
├── IP_NOTICE.md                       # Open research distribution terms
├── diabetes121212.html               # USPTO Patent Center submission receipt
├── diabetes121212_files/             # Web assets from patent submission
└── findings/                         # Research reports
    ├── DIABETES_CURE_FINAL_REPORT.md                    # Complete final report
    ├── DIABETES_CURE_SUMMARY.md                         # Quick summary
    ├── DIABETES_CURE_REPORT.md                          # Initial discovery report
    ├── DIABETES_CURE_KNOWN_PROPERTIES_REPORT.md         # Known properties research
    └── DIABETES_CURE_KNOWN_PROPERTIES_REPORT_V2.md      # Extended properties research

Research Reports

1. DIABETES_CURE_FINAL_REPORT.md

Complete Discovery & Analysis Report

• Full Alchemy Data V2 search results
• Literature cross-reference validation
• Scientific evidence and mechanisms
• Assessment of findings
• Next steps and recommendations

2. DIABETES_CURE_SUMMARY.md

Quick Summary

• Database search results overview
• Top findings
• Research statistics

3. DIABETES_CURE_KNOWN_PROPERTIES_REPORT_V2.md

Extended Known Properties Research

• Detailed scientific evidence from literature
• Published properties of zinc-amino acid complexes
• Specific compounds studied
• Mechanism of action

Key Findings Summary

• 14 research compounds identified through Alchemy Data V2
• Top candidate: C-H-O-N-Zn identified
• Literature cross-references show elemental overlap with published research
• Published compounds share structural elements with findings
• Scientific context established from published literature

Assessment

Factors Supporting Further Research:

• Overlaps with published compounds (elemental match)
• Published mechanisms involve same elements
• Published effectiveness in animal models (for related compounds)
• Strong scientific literature base
• Active research area

Factors Requiring Caution:

• Human clinical trials needed
• Clinical validation needed
• Long-term safety unknown
• These specific compounds have not been synthesized or tested

Overall Assessment: These findings warrant further investigation through proper scientific channels.

Important Disclaimers

Medical Disclaimer:

These are RESEARCH FINDINGS, NOT PROVEN TREATMENTS.

• Compounds identified through Alchemy Data V2 computational analysis
• Properties cross-referenced against published literature
• NOT tested in humans
• NOT approved medications
• NOT proven to treat or cure diabetes

Research Status:

• Compounds identified computationally
• Elemental overlap with published research confirmed
• Mechanisms proposed based on literature
• NOT synthesized for this purpose
• NOT tested in diabetic animals for this research
• NOT tested in humans
• NOT FDA approved

Required Steps for Validation:

1. Synthesis - Create specific compounds

2. Cell Studies - Test on beta cells

3. Animal Studies - Test on diabetic animals

4. Safety Studies - Human safety testing

5. Clinical Trials - Efficacy studies

6. FDA Approval - Regulatory approval

This is early-stage computational research.

Next Steps

1. Synthesis - Create specific C-H-O-N-Zn compounds

2. In Vitro Studies - Test on beta cells and insulin-producing cells

3. Animal Studies - Test on type 1 and type 2 diabetic animals

4. Mechanism Studies - Detailed mechanism of action research

5. Safety Studies - Human safety testing

6. Clinical Trials - Efficacy studies in humans

References

All scientific evidence and references are documented in the reports in the findings/ directory. Key published studies include:

• PubMed study (PMID: 11383627) - Zinc(II) Complex with L-Threonine
• PubMed study (PMID: 18989849) - Zinc(II)/Poly(gamma-glutamic acid) Complex
• Multiple additional studies on zinc-amino acid complexes for diabetes

Contact

Author: Christopher Gabriel Brown

Email: crioneaka@outlook.com

System: Alchemy Data V2

Project 10 - Open Research: Diabetes Mechanism Analysis

Freely distributed for educational and research purposes. Use at your own risk.

Safety Disclaimer

Safety Disclaimer

THIS IS NOT MEDICAL ADVICE. THIS IS NOT AN FDA-APPROVED TREATMENT.

This project contains computational research findings from an elemental analysis database. The compounds described here have NOT been:

• Synthesized for medical use
• Tested in cell cultures, animals, or humans
• Reviewed or approved by any regulatory agency
• Validated through clinical trials

DO NOT attempt to self-treat any medical condition based on this research.

If you are interested in any compound mentioned here, consult a licensed physician or pharmacist before taking any action. Many elements and compounds discussed (zinc, copper, iron, etc.) can be toxic at improper doses.

Known Safety Concerns:

• Zinc supplementation >40 mg/day can cause copper deficiency, anemia, and neurological damage
• Iron overload causes organ damage (hemochromatosis risk)
• Copper excess is hepatotoxic
• Metal-amino acid complexes have unknown safety profiles in humans
• Drug interactions with existing medications are possible and unstudied

USE THIS INFORMATION AT YOUR OWN RISK.

This research is shared freely for educational purposes. The author (Christopher Gabriel Brown) makes no warranties about the accuracy, completeness, or therapeutic potential of any findings herein.

DIABETES Research Notes DISCOVERY - DISCOVERY SUMMARY REPORT

DIABETES CURE DISCOVERY - DISCOVERY SUMMARY REPORT

Alchemy Data V2 Database Search Results

Date: January 12, 2026

System: Christopher Gabriel Brown's Alchemy Data V2

Search Type: Comprehensive cure-focused database search

SEARCH RESULTS SUMMARY

Database Search Completed:

• 11 cure-focused compounds discovered
• 9 cure mechanisms identified
• Top candidate: C-H-O-N
• Top Score: 50.5/100

Top Discovery:

C-H-O-N

• Score: 50.5/100
• Probability: 0.010094
• Mechanisms: Cell regeneration, Beta cell regeneration, Insulin regeneration, Growth factors
• Transformations: 10
• Synthesis Methods: 1

DISCOVERY STATISTICS

• Cell regeneration: 11 compounds
• Beta cell regeneration: 11 compounds
• Insulin regeneration: 11 compounds
• Growth factors: 11 compounds
• Glucose metabolism restoration: 10 compounds
• Insulin signaling pathway activation: 8 compounds
• Glycogen synthesis: 2 compounds
• Insulin sensitivity improvement: 2 compounds

TOP 10 COMPOUNDS

1. C-H-O-N

• Score: 50.5/100
• Probability: 0.010094
• Mechanisms: Cell regeneration, Beta cell regeneration, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

2. C-H-O-N-S

• Score: 50.2/100
• Probability: 0.003296
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

3. C-H-O-N-P

• Score: 50.2/100
• Probability: 0.003273
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Glycogen synthesis, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

4. C-H-O-N-Zn

• Score: 50.1/100
• Probability: 0.002757
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

5. C-H-O-N-Mg

• Score: 50.1/100
• Probability: 0.002079
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin regeneration, Insulin sensitivity improvement, Growth factors
• Transformations: 10 | Synthesis: 1

6. C-H-O-N-S-Zn

• Score: 50.0/100
• Probability: 0.000919
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

7. C-H-O-N-P-Zn

• Score: 50.0/100
• Probability: 0.000912
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Glycogen synthesis, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

8. C-H-O-N-Cu-Zn

• Score: 50.0/100
• Probability: 0.000827
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

9. C-H-O-N-Fe-Zn

• Score: 50.0/100
• Probability: 0.000790
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Growth factors
• Transformations: 10 | Synthesis: 1

10. C-H-O-N-Zn-Mg

• Score: 50.0/100
• Probability: 0.000580
• Mechanisms: Cell regeneration, Glucose metabolism restoration, Beta cell regeneration, Insulin signaling pathway activation, Insulin regeneration, Insulin sensitivity improvement, Growth factors
• Transformations: 10 | Synthesis: 1

---

This archive contains 48 documents; 38 more beyond this preview. The complete folder ships as the product.